**Assertio Holdings Receives Notice of Non-Compliance from Nasdaq: Stock Price Below Minimum Requirement**

Assertio Holdings, Inc. (NASDAQ: ASRT) recently disclosed in a Form 8-K filing with the Securities and Exchange Commission that it received a notice from The Nasdaq Stock Market. The notice indicated that the company’s common stock is at risk of delisting from the Nasdaq Capital Market due to its failure to meet the minimum bid price requirement of $1.00 per share for 32 consecutive business days.

While the notice does not lead to an immediate delisting, Assertio Holdings has until July 21, 2025, to regain compliance with the bid price rule. Nasdaq has provided a window for the stock to reach or exceed $1.00 per share for at least ten consecutive business days to demonstrate compliance. If the company fails to meet the requirement by the compliance date, it may be eligible for an additional 180-day period to regain compliance.

Assertio Holdings expressed its commitment to actively monitoring its stock price and exploring available options to align with the bid price rule. However, the company also noted that there are no assurances of regaining compliance within the specified timeline.

In response to the potential delisting, Assertio Holdings intends to focus on strategies to address the bid price deficiency and ensure continued compliance with Nasdaq’s listing requirements.

The company’s shares have experienced fluctuations in recent periods, and stakeholders will be closely watching as Assertio navigates the process to restore compliance and maintain its listing on the Nasdaq Capital Market. Investors and market analysts will likely monitor how Assertio’s management responds to this development and the impact it may have on the stock’s performance moving forward.

The article reflects Assertio Holdings’ current situation and the steps it plans to take to address the bid price rule non-compliance issue. Market participants await further updates from the company regarding its efforts to meet Nasdaq’s listing standards and potentially avoid delisting.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Assertio’s 8K filing here.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.